Literature DB >> 9110385

Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes.

E A Kramár1, J W Harding, J W Wright.   

Abstract

Our laboratory has previously reported the discovery of a unique angiotensin binding site (termed AT4) specific for angiotensin IV (AngIV) in cultured vascular endothelial and smooth muscle cells. The present investigation employed laser-Doppler flowmetry to examine the effect of angiotensin II (AngII) and AngIV stimulation of these receptors on cerebral microcirculation in anesthetized Sprague-Dawley rats. Internal carotid artery infusion of AngII at a low dose (0.1 pmol min-1) revealed a 23% reduction in cerebral blood flow (CBF), while the infusion of AngIV increased CBF in a dose-dependent fashion with the highest dose (100 pmol min-1) resulting in an elevation of 30%. In a second experiment separate groups of rats were pre-treated with the AT1 receptor subtype antagonist DuP 753 (Losartan), the AT2 receptor subtype antagonist PD123177, or a newly synthesized AT4 receptor subtype antagonist Divalinal-AngIV (Divalinal), followed by AngII or AngIV for the purpose of determining which angiotensin receptor subtype is responsible for mediating these AngII- and AngIV-induced responses. Pre-treatment with Losartan completely blocked subsequent AngII-induced reductions in CBF, while both PD123177 and Divalinal failed to inhibit this response. In contrast, significant increases in CBF were measured due to AngIV stimulation following pre-treatment with Losartan and PD 123177, while Divalinal abolished this AngIV-induced response. These results suggest that AngII and IV play opposite roles in cerebral microcirculation, i.e., the AT1 receptor subtype mediates AngII-induced reductions in CBF, while the AT4 receptor subtype regulates increases in CBF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9110385     DOI: 10.1016/s0167-0115(96)02116-7

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  24 in total

Review 1.  Angiotensin and cerebral blood flow.

Authors:  J M Saavedra; Y Nishimura
Journal:  Cell Mol Neurobiol       Date:  1999-10       Impact factor: 5.046

2.  Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning.

Authors:  J W Wright; L Stubley; E S Pederson; E A Kramár; J M Hanesworth; J W Harding
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

Review 3.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 4.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

5.  Angiotensin IV enhances phosphorylation of 4EBP1 by multiple signaling events in lung endothelial cells.

Authors:  Jianghua Lu; Jianalian Zhang; Edward R Block; Jawaharlal M Patel
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

6.  Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.

Authors:  Jessika Royea; Luqing Zhang; Xin-Kang Tong; Edith Hamel
Journal:  J Neurosci       Date:  2017-05-05       Impact factor: 6.167

Review 7.  The role of angiotensin II receptors in stroke protection.

Authors:  Steven G Chrysant
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

8.  Central administration of angiotensin IV rapidly enhances novel object recognition among mice.

Authors:  Jason J Paris; Shainnel O Eans; Elisa Mizrachi; Kate J Reilley; Michelle L Ganno; Jay P McLaughlin
Journal:  Neuropharmacology       Date:  2013-02-14       Impact factor: 5.250

9.  The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.

Authors:  B J Yamamoto; P D Elias; J A Masino; B D Hudson; A T McCoy; Z J Anderson; M D Varnum; M F Sardinia; J W Wright; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

Review 10.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.